论文部分内容阅读
目的研究NAD+依赖性15-羟基前列腺素脱氢酶(15-PGDH)在大肠腺癌组织、大肠腺瘤组织及正常大肠组织中的表达,探讨15-PGDH在大肠腺癌组织中的表达情况及其与大肠腺癌临床病理因素的关系。方法应用免疫组织化学(SABC)法检测40例大肠腺癌组织、20例大肠腺瘤组织和20例正常大肠组织中15-PGDH的表达情况。结果15-PGDH在大肠腺癌(15%)和腺瘤组织(20%)中的阳性表达率显著低于在正常大肠组织(100%)中的阳性表达率(P<0.01),而15-PGDH在大肠腺癌和腺瘤中的表达无统计学差异(P>0.05)。15-PGDH蛋白表达情况与大肠腺癌患者的性别、年龄、分化程度及Dukes分期和有无淋巴结转移等临床病理参数均无关系(P>0.05)。结论大肠腺癌组织中15-PGDH表达减少或缺失,且其表达与大肠腺癌的分期分化等病理参数并无关系。15-PGDH的表达缺失或减少可能发生在大肠腺癌发生发展的早期,是大肠腺癌发生的抑制物。
Objective To study the expression of NAD + -dependent 15-hydroxyprostaglandin dehydrogenase (15-PGDH) in colorectal adenocarcinoma, colorectal adenoma and normal colorectal tissues and to investigate the expression of 15-PGDH in colorectal adenocarcinoma Its relationship with clinicopathological factors of colorectal adenocarcinoma. Methods The expression of 15-PGDH in 40 cases of colorectal adenocarcinoma, 20 cases of colorectal adenoma and 20 cases of normal colorectal tissues was detected by immunohistochemistry (SABC). Results The positive rate of 15-PGDH in colorectal adenocarcinoma (15%) and adenoma (20%) was significantly lower than that in normal colorectal tissues (100%) (P <0.01) The expression of PGDH in colorectal adenocarcinoma and adenoma showed no significant difference (P> 0.05). There was no correlation between the expression of 15-PGDH protein and the clinicopathological parameters (P> 0.05), such as gender, age, differentiation degree, Dukes staging and lymph node metastasis. Conclusion The expression of 15-PGDH in colorectal adenocarcinoma is reduced or absent, and the expression of 15-PGDH is not related to the pathological parameters such as staging and differentiation of colorectal adenocarcinoma. 15-PGDH loss of expression or reduction may occur in the early development of colorectal adenocarcinoma, is an inhibitor of colorectal adenocarcinoma.